Polsinelli Podcasts - FDA Denies Amgen Citizen Petition in Biosimilar Dispute
Drug Company’s Mandatory Release of Price Increase May Compromise Privilege, Permitting Disclosure Under the CPRA - A California appellate court recently held that disclosure of trade secret information to third parties,...more
In a seriously fractured decision, the Federal Circuit construed the provisions of the Biologics Price Control and Innovation Act (BPCIA or Act) in Amgen Inc. et al. v. Sandoz Inc. In doing so, the court limited the...more
The Evolving World of Biosimilars - Amgen, Inc. v. Sandoz, Inc. Addressing two new issues in the Biologics Price Competition and Innovation Act (BPCIA), the Northern District of California issued an order, on...more